Docoh
Loading...
Sign up Log in

TXMD TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.

Company profile

Ticker
TXMD
Exchange
NASDAQ
Website
www.therapeuticsmd.com/
CEO
Robert Finizio
Employees
Incorporated
Nevada
Location
Florida
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...
Former names
AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
SEC CIK
0000025743
Corporate docs
IRS number
870233535

TXMD stock data

(
)

News

Pro users get this 30m faster
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
1 Aug 21
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
19 Jul 21
Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
28 Stocks Moving in Friday's Pre-Market Session
9 Jul 21
12 Health Care Stocks Moving In Wednesday's After-Market Session
9 Jun 21

Press releases

Pro users get this 30m faster
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
26 Jul 21
-Executive Management to Host Conference Call on August 4, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its second
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
25 May 21
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, announced today that the Company submitted a supplemental New Drug Application ("sNDA") for BIJUVA (estradiol and progesterone)
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
24 May 21
TherapeuticsMD, Inc. (NASDAQ:TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee
TherapeuticsMD Announces First Quarter 2021 Financial Results
6 May 21
TherapeuticsMD, Inc. to Host Earnings Call
6 May 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 21
4 Aug 21
31 Dec 21

Financial summary

Financial statements Chart TXMD financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 137.62M 137.62M 137.62M 137.62M 137.62M 137.62M
Cash burn (monthly) (positive/no burn) 2.71M 13.13M 13.84M 12.79M 13.23M
Cash used (since last report) n/a 11.2M 54.33M 57.27M 52.94M 54.74M
Cash remaining n/a 126.42M 83.29M 80.35M 84.67M 82.87M
Runway (months of cash) n/a 46.7 6.3 5.8 6.6 6.3

Beta Read what these cash burn values mean

Recent insider trades

TXMD insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 21 Donegan Michael C RSU Common Stock Grant Aquire A No No 0 80,000 0 80,000
1 Jul 21 Donegan Michael C Performance Stock Units Common Stock Grant Aquire A No No 0 160,000 0 160,000
1 Jul 21 James DArecca RSU Common Stock Grant Aquire A No No 0 173,333 0 173,333
1 Jul 21 James DArecca Performance Stock Units Common Stock Grant Aquire A No No 0 346,667 0 346,667
1 Jul 21 Marlan D Walker RSU Common Stock Grant Aquire A No No 0 173,333 0 173,333
1 Jul 21 Marlan D Walker Performance Stock Units Common Stock Grant Aquire A No No 0 346,667 0 346,667
1 Jul 21 Borkowski Edward RSU Common Stock Grant Aquire A No No 0 186,667 0 186,667
1 Jul 21 Borkowski Edward Performance Stock Units Common Stock Grant Aquire A No No 0 373,333 0 373,333
1 Jul 21 Finizio Robert G RSU Common Stock Grant Aquire A No No 0 746,667 0 746,667
1 Jul 21 Finizio Robert G Performance Stock Units Common Stock Grant Aquire A No No 0 1,493,333 0 1,493,333
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

TXMD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

44.2% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 160 159 +0.6%
Opened positions 28 32 -12.5%
Closed positions 27 13 +107.7%
Increased positions 61 45 +35.6%
Reduced positions 28 39 -28.2%
13F shares
 Current Prev Q Change
Total value 308.83M 470.51M -34.4%
Total shares 173.95M 161.08M +8.0%
Total puts 968.2K 853.1K +13.5%
Total calls 1.02M 573K +77.9%
Total put/call ratio 0.9 1.5 -36.2%
Largest owners
 Shares Value Change
BLK Blackrock 27.6M $36.98M +28.8%
TROW T. Rowe Price 18.31M $24.54M -2.9%
Vanguard 18.09M $24.24M +37.4%
FMR 13.91M $18.63M -1.5%
Ra Capital Management 7.81M $10.47M 0.0%
MS Morgan Stanley 7.32M $9.81M -21.1%
STT State Street 7.18M $9.63M +62.2%
AXAHF Axa 6.71M $8.99M +49.2%
C WorldWide Group Holding A/S 6.19M $8.29M 0.0%
Geode Capital Management 5.56M $7.45M +46.1%
Largest transactions
 Shares Bought/sold Change
BLK Blackrock 27.6M +6.18M +28.8%
GMT Capital 0 -5.99M EXIT
Vanguard 18.09M +4.93M +37.4%
Handelsbanken Fonder AB 0 -3.25M EXIT
STT State Street 7.18M +2.75M +62.2%
Perceptive Advisors 2.75M +2.75M NEW
Millennium Management 2.71M +2.55M +1553.6%
AXAHF Axa 6.71M +2.21M +49.2%
MS Morgan Stanley 7.32M -1.96M -21.1%
Geode Capital Management 5.56M +1.75M +46.1%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Amag Pharmaceuticals • Agile Therapeutics • Allergan • Mylan II B.V. • Amneal Pharmaceuticals
Management Discussion
  • Revenue and gross profit.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Good
New words: API, ATM, aware, broker, Cantor, Chew, conclusion, conform, core, deemed, deficit, Deposit, Description, devote, dietary, dollar, duly, energy, expenditure, fail, FileNo, Finizio, Fitzgerald, FOLMAX, Furnished, gluten, heading, herewith, hold, Inline, issuer, John, kosher, lab, macroeconomic, member, mendment, Milligan, Mine, Multivitamin, mutually, Notwithstanding, OfferingSM, ofour, oil, omitted, onboarded, onboarding, optimized, orgreater, overnight, page, past, pathway, Pearl, premium, proper, proprietary, raw, reclassified, Reform, remining, Robert, rounding, Rx, sample, satisfactorily, Senior, sentence, shown, Street, sugar, suggested, Tao, thecurrent, thereunto, thousand, True, unamortized, undersigned, underwriting, Unregistered, unrounded, unsecured, vagina, vegan, vitaTrue, volume, XBRL
Removed: ACA, acceptable, accessed, accrue, achieved, achieving, acquire, acquired, addendum, addressable, adequate, adherence, adjudicating, adjudication, advance, affordability, Africa, allocable, allocate, allocated, America, AmerisourceBergen, amortize, amortizing, annually, applied, apply, appointed, approximately, Argentina, Article, ASC, assist, assisting, assumed, assumption, ASU, attained, attaining, attainment, attractive, audited, Australia, authorization, award, banking, bankruptcy, batch, began, behavior, belief, billing, billion, Boca, BocaGreen, bore, bothersome, Brazil, breach, breadth, broad, broader, build, calculating, calling, cancelling, candidate, capitalize, Cardinal, Carroll, categorize, categorized, category, Certified, cessation, China, Codification, combined, commence, commenced, commencement, communicate, communication, comparable, compete, competent, Competition, compounded, compounding, comprehensive, comprised, compute, conducting, consecutive, conserve, consistency, consistently, constitute, consulting, consumed, contemporaneously, context, contingency, contingent, contractual, convert, corroboration, country, coupon, created, creation, critical, CRO, cured, custom, customary, cycle, damage, decision, declare, decreased, dedicated, default, Defense, Delaware, delivered, demonstrating, Department, depicting, derivative, derived, designated, desired, detail, detailed, detailing, developed, dialogue, digital, direct, disbursed, disclose, discounted, discrete, discretion, displaced, dissatisfied, dissolution, divided, dividend, drawn, economy, educate, electricity, eliminate, eliminating, emerging, employ, employment, enacted, energizing, enroll, ensuring, entitle, environment, EPS, equivalent, escalating, established, Establishing, estate, EUR, Europe, evolved, excluded, exclusively, exclusivity, expand, expanded, expanding, experiencing, expiring, extended, extension, external, extinguishment, family, FASB, fashion, favorable, federally, feet, field, fill, filling, focusing, foregoing, foreign, foresee, forfeited, forfeiture, formed, formulation, foundation, free, fulfillment, functional, gain, generated, globally, good, guaranteed, Guide, handling, HCP, hierarchy, high, hybrid, identical, identification, identify, immaterial, impacted, implicit, improved, inception, inclusion, incremental, index, indirect, inhibit, initially, initiative, input, insignificant, Institute, instrument, intention, interaction, interruption, introduced, introduction, investigational, investigative, involve, involvement, IP, Japan, joint, judgment, KAM, key, Korea, larger, largest, launch, leading, learn, lease, leased, lender, lever, leveraging, lien, lift, likelihood, limit, liquidation, location, lost, lowest, lunch, managed, mandatory, manner, manufactured, maturing, McKesson, measured, Measurement, media, medication, methodology, Mexico, MidCap, mind, minimizing, model, modified, modify, motived, NA, NaN, NCE, necessarily, negative, negotiate, Nestorone, nonrefundable, NuvaRing, observable, observed, obtained, October, offline, ongoing, OPERA, operate, organization, originally, outbreak, overhead, overseeing, oversight, par, partial, patch, pause, Paycheck, paying, peer, pending, percent, perfected, permanent, perpetual, Pharma, physician, Pillpack, pipeline, planned, planning, platform, positioning, post, PPP, preclinical, predicted, predisposed, predominately, preferred, premier, prepared, preparing, prepay, prescribed, prescribing, present, priority, pro, profitability, promissory, promotion, prospective, prospectively, protocol, publicly, Puerto, pull, qualified, quickly, quoted, ramp, ramping, ranging, rata, ratably, ratio, Raton, real, realized, reassessed, receive, recent, refer, refill, reflected, registered, relate, released, relevant, reliably, remeasurement, remotely, rent, rentable, repay, reportable, reputation, requisite, responded, responsibility, restarted, Restoration, resulting, retaining, retrospective, retrospectively, reverse, reviewing, revision, Rico, ring, royalty, Russia, scientific, scope, sector, secured, securing, security, seek, segment, Select, selected, separate, separately, September, serve, serving, setting, sharing, sheet, shipping, shortage, show, simplified, SM, sooner, South, space, span, speak, spend, spending, spread, square, stage, standard, step, stockholder, strategic, streamline, sublicense, subsequent, substantially, sum, superseded, supplied, sustain, symbol, target, targeted, Task, team, tendered, terminate, terminated, termination, territory, test, Title, Topic, TPG, traded, traditional, training, tranche, transdermal, transfer, transferred, transition, transitioned, Treasury, treat, Trust, TXMD, typically, unadjusted, unallocated, unaudited, unbranded, unconditional, underlying, underrepresented, understanding, undertaken, undiscounted, unfunded, universe, unobservable, unrecognized, unvested, upfront, utility, utilization, vest, Veteran, view, visit, VitaMed, VMS, VVA, Washington, wholly, withheld, withholding, worldwide, writing, wrote, yield, Zealand
From filing 10-Q 2021 Q1

Financial reports

View all
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
3 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K/A
2019 FY
Annual report (amended)
28 Apr 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19

Current reports

View all
8-K
Departure of Directors or Certain Officers
28 May 21
8-K
TherapeuticsMD Announces First Quarter 2021 Financial Results
6 May 21
8-K
Departure of Directors or Certain Officers
12 Apr 21
8-K
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
2 Mar 21
8-K
Entry into a Material Definitive Agreement
16 Feb 21
8-K
Entry into a Material Definitive Agreement
13 Jan 21
8-K
Entry into a Material Definitive Agreement
27 Nov 20
8-K
Entry into a Material Definitive Agreement
12 Nov 20
8-K
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
9 Nov 20
8-K
Regulation FD Disclosure
14 Sep 20

Registration and prospectus

View all
S-8
Registration of securities for employees
7 Jun 21
S-3ASR
Automatic shelf registration
3 Mar 21
424B2
Prospectus for primary offering
16 Feb 21
424B5
Prospectus supplement for primary offering
10 Feb 21
424B5
Prospectus supplement for primary offering
27 Nov 20
424B2
Prospectus for primary offering
12 Nov 20
424B5
Prospectus supplement for primary offering
9 Nov 20
D
$7.5M in options / securities to be acquired, sold $7.5M, 3 investors
14 Aug 20
S-8
Registration of securities for employees
7 Aug 20
POS AM
Prospectus update (post-effective amendment)
24 Feb 20

Proxies

View all
DEFA14A
Additional proxy soliciting materials
21 May 21
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
PRE 14A
Preliminary proxy
1 Apr 21
DEFA14A
Additional proxy soliciting materials
4 May 20
DEF 14A
Definitive proxy
4 May 20
PRER14A
Preliminary revised proxy
22 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEF 14A
Definitive proxy
29 Apr 19

Other

View all
EFFECT
Notice of effectiveness
6 May 20
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
20 Aug 18
UPLOAD
Letter from SEC
5 Feb 17
CORRESP
Correspondence with SEC
30 Jan 17
UPLOAD
Letter from SEC
24 Jan 17
CORRESP
Correspondence with SEC
28 Dec 16
UPLOAD
Letter from SEC
14 Dec 16
EFFECT
Notice of effectiveness
16 Nov 15

Ownership

View all
SC 13G
TherapeuticsMD / Flynn James E ownership change
7 Jul 21
4
TherapeuticsMD / Karen Ling ownership change
2 Jul 21
4
TherapeuticsMD / J MARTIN CARROLL ownership change
2 Jul 21
4
TherapeuticsMD / JULES A. MUSING ownership change
2 Jul 21
4
TherapeuticsMD / Angus C. Russell ownership change
2 Jul 21
4
TherapeuticsMD / Gail K Naughton ownership change
2 Jul 21
4
TherapeuticsMD / PAUL BISARO ownership change
2 Jul 21
4
TherapeuticsMD / Cooper C. Collins ownership change
2 Jul 21
4
TherapeuticsMD / Tommy G Thompson ownership change
2 Jul 21
4
TherapeuticsMD / Robert G Finizio ownership change
2 Jul 21

Patents

View all
GRANT
Utility
Soluble estradiol capsule for vaginal insertion
20 Jul 21
According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided.
GRANT
Utility
Progesterone formulations having a desirable pk profile
15 Jun 21
This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters.
GRANT
Utility
Formulations for solubilizing hormones
9 Feb 21
Compositions and methods for the solubilization of steroid hormones are disclosed.
GRANT
Utility
Soluble estradiol capsule for vaginal insertion
12 Jan 21
According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided.
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
16 Nov 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.

Transcripts

View all
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
9 Nov 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
20 Feb 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
6 May 19
2018 Q4
Earnings call transcript
22 Feb 19

Reddit threads

View all